Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Freeman

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|December 8, 2019
Five-year Pan-European, longitudinal surveillance of Clostridium difficile ribotype prevalence and antimicrobial resistance: the extended ClosER studyJane Freeman, Jonathan Vernon, Sally Pilling, et al.
Genome Announcements|March 28, 2015
Complete Genome Sequence of the Hypervirulent Bacterium Clostridium difficile Strain G46, Ribotype 027Tom Gaulton, Raju Misra, Graham Rose, et al.
The Journal of Antimicrobial Chemotherapy|August 18, 2012
Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut modelJane Freeman, Miriam Marquis, Grace S Crowther, et al.
Jac-Antimicrobial Resistance|July 24, 2024
Antimicrobial susceptibility in <i>Clostridioides difficile</i> varies according to European region and isolate sourceJane Freeman, Virginie Viprey, Duncan Ewin, et al.
The Journal of Antimicrobial Chemotherapy|April 21, 2011
Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut modelSimon D Baines, Alan R Noel, Grace S Huscroft, et al.
The Lancet. Digital Health|November 15, 2024
Innovative diagnostic technologies: navigating regulatory frameworks through advances, challenges, and future prospectsJesus Rodriguez-Manzano, Sumithra Subramaniam, Chibuzor Uchea, et al.
Frontiers in Endocrinology|October 13, 2017
Cross Talk between Adipose Tissue and Placenta in Obese and Gestational Diabetes Mellitus Pregnancies <i>via</i> ExosomesNanthini Jayabalan, Soumyalekshmi Nair, Zarin Nuzhat, et al.
Ebiomedicine|May 1, 2019
Clostridium difficile trehalose metabolism variants are common and not associated with adverse patient outcomes when variably present in the same lineageDavid W Eyre, Xavier Didelot, Anthony M Buckley, et al.
Plos One|May 22, 2013
Short-term genome stability of serial Clostridium difficile ribotype 027 isolates in an experimental gut model and recurrent human diseaseDavid W Eyre, A Sarah Walker, Jane Freeman, et al.
The Journal of Antimicrobial Chemotherapy|April 20, 2021
Haem is crucial for medium-dependent metronidazole resistance in clinical isolates of Clostridioides difficileIlse M Boekhoud, Igor Sidorov, Sam Nooij, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|December 8, 2019
Five-year Pan-European, longitudinal surveillance of Clostridium difficile ribotype prevalence and antimicrobial resistance: the extended ClosER studyJane Freeman, Jonathan Vernon, Sally Pilling, et al.
Genome Announcements|March 28, 2015
Complete Genome Sequence of the Hypervirulent Bacterium Clostridium difficile Strain G46, Ribotype 027Tom Gaulton, Raju Misra, Graham Rose, et al.
The Journal of Antimicrobial Chemotherapy|August 18, 2012
Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut modelJane Freeman, Miriam Marquis, Grace S Crowther, et al.
Jac-Antimicrobial Resistance|July 24, 2024
Antimicrobial susceptibility in <i>Clostridioides difficile</i> varies according to European region and isolate sourceJane Freeman, Virginie Viprey, Duncan Ewin, et al.
The Journal of Antimicrobial Chemotherapy|April 21, 2011
Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut modelSimon D Baines, Alan R Noel, Grace S Huscroft, et al.
The Lancet. Digital Health|November 15, 2024
Innovative diagnostic technologies: navigating regulatory frameworks through advances, challenges, and future prospectsJesus Rodriguez-Manzano, Sumithra Subramaniam, Chibuzor Uchea, et al.
Frontiers in Endocrinology|October 13, 2017
Cross Talk between Adipose Tissue and Placenta in Obese and Gestational Diabetes Mellitus Pregnancies <i>via</i> ExosomesNanthini Jayabalan, Soumyalekshmi Nair, Zarin Nuzhat, et al.
Ebiomedicine|May 1, 2019
Clostridium difficile trehalose metabolism variants are common and not associated with adverse patient outcomes when variably present in the same lineageDavid W Eyre, Xavier Didelot, Anthony M Buckley, et al.
Plos One|May 22, 2013
Short-term genome stability of serial Clostridium difficile ribotype 027 isolates in an experimental gut model and recurrent human diseaseDavid W Eyre, A Sarah Walker, Jane Freeman, et al.
The Journal of Antimicrobial Chemotherapy|April 20, 2021
Haem is crucial for medium-dependent metronidazole resistance in clinical isolates of Clostridioides difficileIlse M Boekhoud, Igor Sidorov, Sam Nooij, et al.
Pageof 6